Epidemiology and costs of screening and management of precancerous lesions of the cervix

Journal of Lower Genital Tract Disease

Volumn 13, Issue 1, 2009, Pages 38-45

  Castellsagué, Xavier ^a   Rémy, Vanessa ^b   Puig Tintoré, Luis M ^c   De La Cuesta, Ricardo Sainz ^d   Gonzalez Rojas, Nuria ^e   Cohet, Catherine ^b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b SANOFI PASTEUR   (France)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL QUIRÓN   (Spain)

^e Adelphi Targis   (Spain)

Author keywords

Cervical screening; Costs; Epidemiology; Human papillomavirus; Precancerous lesions

Indexed keywords

ARTICLE; CANCER SCREENING; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CENTER; HUMAN; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRECANCER; SPAIN; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH CARE COSTS; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; RETROSPECTIVE STUDIES; SPAIN; VAGINAL SMEARS;

EID: 58549117183     PISSN: 10892591     EISSN: None     Source Type: Journal    
DOI: 10.1097/LGT.0b013e318182cd89     Document Type: Article

References (21)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. 2004 ed. IARC Cancer Base No. 5. version 2.0. Lyon: IARCPress; 2004.
2. Bray F, Loos AH, McCarron P, Weiderpass E, Arbyn M, Moller H, et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 2005; 14:677-86.
3. Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Borras J, et al. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer 2000;86:429-35.
4. Llorca J, Rodriguez-Cundin P, Dierssen-Sotos T, Prieto-Salceda D. Cervical cancer mortality is increasing in Spanish women younger than 50. Cancer Lett 2006;240: 36-40.
5. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
6. Fernandez Calvo MT, Hernandez RA, Rosell A, I. Cervical cancer screening in Spain. Eur J Cancer 2000;36:2250-4.
7. Puig-Tintore LM, Castellsague X, Tome A, de SS, Cortes J, Roura E, et al. Coverage and factors associated with cervical cancer screening: results from the AFRODITA study: a population-based survey in Spain. J Low Genit Tract Dis 2008; 12:82-9.
8. Cantor SB, Atkinson EN, Cardenas-Turanzas M, Benedet JL, Follen M, MacAulay C. Natural history of cervical intraepithelial neoplasia-a meta-analysis. Acta Cytol 2005;49: 405-15.
9. de Sanjosé S, Cortes J, Mendez C, Tomé A, Roura E. Age at sexual initiation and number of sexual partners in the female Spanish population. Results from the AFRODITA survey. Eur J Obstet Gynecol Reprod Biol 2008. In press.
10. Brown RE, Breugelmans JG, Theodoratou D, Benard S. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 2006;22:663-70.
11. Bergeron C, Breugelmans JG, Bouee S, Lorans C, Benard S, Remy V. Cervical cancer screening and associated treatment costs in France. Gynecol Obstet Fertil 2006;34:1036-42.
12. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 2005;23:1107-22.
13. Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol 2004;191:114-20.
14. Luengo Matos S, Muñoz van den Eynde A. Use of Pap smear for cervical cancer screening and factors related with its use in Spain. Aten Primaria 2004;33:229-34.
15. Luengo Matos S, Muñoz van den Eynde A. Use of Mammography and Pap Tests for Early Detection of Breast and Cervical Cancer in Spain. Madrid: Agencia de Evaluación de Tecnologías Sanitarias, Instituto de Salud Carlos III-Ministerio de Sanidad y Consumo; 2002.
16. Bergeron C, Carrier I, Guldner L, Lassalle M, Savignoni A, Asselain B. Precancerous lesions and cervical cancer diagnosed by cervical Pap smear, Ile-de-France, Crisap survey, 2002. BEH 2005; 2005:5-6. Available at: http://www.invs.sante.fr/beh/2005/02/beh-02-2005.pdf. Accessed on June 30, 2008.
17. Giorgi Rossi P, Largeron N, Cohet C, Palazzo F, Mennini FS, Furnari G, Federici A, Valle S. Impact and cost of cervical cancer prevention in Italy. Abstract. 4th Annual Meeting of Health Technology Assessment International (HTAi); Barcelona, Spain; 2007.
18. Petry KU, Breugelmans JG, Benard S, Lamure E, Little-wood KJ, Hillemans P. Cost of screening and treatment of cervical dyskaryosis in Germany. Eur J Gynaecol Oncol 2008. In press.
19. Schmolling Guinovart Y, Barquín Solera JJ, Zapata Ingelmo A, Merino Segovia R, Rodríguez Martínez B, León González E. Cell anomalies in the cervix and subsequent precancerous lesions in a Health Area. Aten Primaria 2002; 29:223-9.
20. Volante R, Ronco G. National survey of the quality of 2nd level in screening for cervical cancer. Epidemiol Prev 2006;30(1 suppl 3):51-7.
21. Mata M, Antonanzas F, Tafalla M, Sanz P. The cost of type 2 diabetes in Spain: the CODE-2 study. Gac Sanit 2002; 16:511-20.